Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs Lufax Holding Ltd (LU) Price & Performance

Incyte CorporationTrade
Lufax Holding LtdTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Lufax Holding Ltd — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Lufax Holding Ltd trades at $1.4 (market cap $2.41B). The key difference: Incyte Corporation is far larger — about 9.6× Lufax Holding Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.

INCYLU
Market Cap
$23.11B$2.41B
Sector
HealthTechnology
52-Week High
$118.52$4.40
52-Week Low
$67.38$1.23
Enterprise Value
$19.13B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About Lufax Holding Ltd

Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.

Read more on LU